A fter appropriate stimulation, differentiated epithelial cells are able to adopt a mesenchymal genetic program and form mesenchymal-like cells, such as myofibroblasts, via the process of epithelial mesenchymal transdifferentiation (EMT) (1) (2) (3) . In recent years, an increasing amount of data indicate that EMT may play a pivotal role in the pathogenesis of fibrotic diseases in which myofibroblastic cells become prominent (4 -7) . Thus, understanding the molecular mechanism of EMT may provide opportunities to formulate new therapeutic interventions.
In a previous study, we investigated the effect of activated PBMC conditioned medium (aPBMC-CM) on human proximal tubular epithelial cell to myofibroblast transdifferentiation. We quantified some putatively active components of aPBMC-CM, including TGF-␤1, EGF, IL-1␤, IL-2, IL-6, OSM, GM-CSF, TNF-␣, and INF-␥ (8) . Neutralizing antibodies to each of these did not provide significant protection against the changes initiated by aPBMC-CM. For example, immunoneutralization of TGF-␤1 in aPBMC-CM resulted in only 20% inhibition of EMT (8) . The results suggested that multiple cytokines, including TGF-␤1, simultaneously activate a number of cellular receptors, initiating signals through key molecular cascades that finally lead to transcriptional regulation of EMT gene expression.
Anticipating that aPBMC-CM would trigger complex changes, we used microarray analysis to uncover possible common pathways that drive EMT. A group of small RhoGTPases, including RhoE, RhoG, RhoA, Rac1, and Cdc42, were found to be associated with aPBMC-CM-mediated EMT. Small RhoGTPases are a subset of the Ras superfamily of GTPases and consist of six subfamilies, including the RhoA-related subfamily, the Rac1-related subfamily, and the Cdc42-related subfamily and others (9) . RhoGTPases cycle between an active GTP-bound state and an inactive GDPbound state (9, 10) , a process controlled by specialized regulators, Rho guanine nucleotide exchange factors (RhoGEF), which are transiently activated by receptor tyrosine kinases (10) . Thus, active RhoGTPases transduce signals from cellsurface receptors to intracellular target molecules and function as essential components of signal transduction pathways that regulate cell growth and differentiation (9) . It is known that the RhoGTPases participate in the regulation of both cadherin-mediated cell-cell adhesion (11) and the actin cytoskeleton (9) , suggesting that they may play key roles in EMT (12) . In this study, we examined the role of RhoA, Rac1, and Cdc42 in EMT of human renal epithelial cells (HK2) induced by aPBMC-CM.
Materials and Methods
Mouse mAb against human E-cadherin, Rac1 (Clone 23A8, which recognizes only 21-kD Rac from human, rat, and mouse), Cdc42 (sc-87, which recognizes only Cdc42 from human, rat, and mouse), phosphopaxillin, and phospho-FAK were purchased from BD Transduction Laboratory (Oxford, UK). Mouse monoclonal anti-human fibronectin-EDA ϩ (EDA) and anti-cytokeratin 19 (K19) were from Abcam Ltd.
(Cambridge, UK). Rabbit polyclonal anti-human RhoA (sc-179, which recognizes only p21 RhoA from human, rat, and mouse) and antiphospho-myosin light chain (Thr18/Ser19) were from Santa Cruz Biotechnology (Santa Cruz, CA 
Cell Culture and Treatment
HK2 cells were cultured and aPBMC-CM prepared as reported previously (8) . HK2 cell cultures at approximately 70% confluence were treated with 30% aPBMC-CM in REGM (BioWhittaker Inc., Walkersville, MD). After treatment (5 min to 48 h), the medium was collected and the cells were processed for analysis by SDS-PAGE and Western blotting. For inhibition experiments, the cells were pretreated for 1 h with 10 M HA1077 or 10 M Y-27632 or for 24 h with 100 g/ml toxin B or 100 g/ml Exoenzyme C3 before the addition of 30% aPBMC-CM. AD293 cells (Stratagene, Amsterdam, Netherlands) were maintained in complete DMEM, supplemented with 10% (vol/vol) heat-inactivated FCS (Life Technologies, Paisley, UK) at 37°C in an atmosphere of 5% CO 2 and were passaged when confluent.
SDS-PAGE and Western Blotting
Cell lysates were prepared in either ice-cold M-PER (Pierce, Cheshire, UK) or RIPA buffer supplemented with proteinase inhibitors (8), protein was measured using the BCA kit (Pierce), and SDS-PAGE and Western blotting were performed as described previously (8) . 
Generation of Recombinant Adenoviruses
Replication-deficient recombinant adenoviruses carrying expression plasmids encoding RhoAQ63L, Rac1Q61L, Cdc42Q61L, and RhoAT19N were generated using the AdEasy XL Adenoviral vector system (Stratagene). Briefly, the corresponding cDNA were cloned into the adenoviral transfer vector, pShuttle-IRES-hrGFP-1 (Stratagene), allowing co-expression of GFP with the FLAG-tagged RhoGTPase mutants. After recombination of linearized shuttle vector and adenovirus backbone vector in Escherichia coli BJ5183, the recombined adenoviral constructs were transfected into XL10 Gold (Stratagene) to allow higher plasmid yield. The resultant recombinant virusmids then were transfected into AD293 (Stratagene). Crude lysates that contained recombinant adenoviruses were prepared as viral stocks and used to infect AD-293 cells for amplification. Adenoviruses were purified using the Adeno-X virus purification kit (BD Transduction). Primary viral stock was serially diluted with complete DMEM supplemented with 10% FCS, and the diluted virus was applied to AD-293 cells that were plated in six-well plates. After incubation, the medium was removed and the cells were overlaid with 1.25% agarose/ growth medium. Plates were incubated at 37°C until plaques formed. Plaques were counted under a light microscope.
Adenoviral Infection
HK2 cells (2 ϫ 10 5 /6-cm dish) were infected with the recombinant adenovirus at titers ranging from a multiplicity of infection (MOI) of 20 to 50 and then incubated in complete REBM supplemented with 0.5% FCS for 48 h. Cells were viewed under an ultraviolet microscope to assess GFP expression. Cells that were infected with dominant negative RhoA were stimulated further with 30% aPBMC-CM for 24 h. The lysates were subjected to pull-down assay for active RhoGTPases and Western blot analysis for EMT markers.
Statistical Analyses
Data are expressed as mean Ϯ 2 SD, unless otherwise stated. Comparisons between control and treated samples were performed using t test for paired data. Values of P Ͻ 0.05 were considered significant. Figure 1A shows the changes in the epithelial cell markers E-cadherin and K19 and in the myofibroblast marker EDA after the addition of 30% aPBMC-CM for various periods (0.5 to 48 h). As reported previously (8) , epithelial markers were lost with time, whereas the myofibroblast marker was increasingly expressed. The effect of aPBMC-CM on the activation of RhoA, Rac1, and Cdc42 in HK2 cells was determined by Western blot analysis after affinity precipitation ( Figure 1B ). This showed that the three RhoGTPases were activated from 25 min up to 48 h after stimulation ( Figure 1C ) and that activation occurred earlier than the changes of EMT markers.
Results

aPBMC-CM Induces EMT via the Activation of RhoA, Rac1, and Cdc42
Inhibitors were used to examine whether activation of RhoGTPases is associated with aPBMC-CM-mediated EMT. HK2 cells were pretreated with either C3 or toxin B for 24 h before stimulation with aPBMC-CM. C3 is regarded as a RhoA subfamily inhibitor (13) , whereas toxin B inhibits almost all members of the RhoGTPases, including RhoA-, Rac1-, and Cdc42-related subfamilies (14) . There were no morphologic changes in the cells that were treated with inhibitors, and MTS assay showed that they had no effect on HK2 cell viability (data not shown). Activation of RhoA after aPBMC-CM stimulation was substantially suppressed in the presence of either inhibitor ( Figure 2 , A and C). Toxin B but not C3 inhibited the aPBMC-CM-mediated activation of Rac1 and Cdc42. Toxin B blocked the loss of E-cadherin and K19 and gain of EDA ( Figure 2 , B and D). C3 prevented gain of EDA but had no effect on loss of E-cadherin and K19. HA1077 and Y27632, inhibitors of Rho kinase (ROCK) (15), a downstream target of RhoA activation, had no effect on aPBMC-CM-induced activation of RhoA, Rac1, and Cdc42; however, they prevented gain of EDA but had no effect on E-cadherin and K19. These data suggest that the transdifferentiation that occurs in response to aPBMC-CM is dependent on signaling through activation of RhoGTPases. 
Transient Expression of Mutant RhoGTPases in HK2 Cells
The use of IRES in the pShuttle-IRES-hrGFP-1 vector allowed the coexpression of GFP and FLAG-tagged RhoGTPases. The presence of GFP-positive cells correlated with the MOI value applied (data not shown). These results agreed well with the increased expression of FLAG in HK2 cells for each adenoviral construct that was found to be proportional to the increased MOI value (Figure 3) , with a LacZ infection control showing no expression of FLAG at the highest MOI value (data not shown).
The levels of active RhoA, Rac1, and Cdc42 also increased with increasing level of the MOI value used for infection of the constitutively active constructs, but infection had no effect on the total level of RhoA, Rac1, and Cdc42 (data not shown). A MOI of 50 achieved approximately the same level of active RhoA, Rac1, and Cdc42 as stimulation of the cells with 30% aPBMC-CM. When cells were infected with virus that contained RhoAT19N and stimulated for an additional 24 h with aPBMC-CM, a MOI of 50 viral-delivered RhoAT19N almost completely blocked the formation of activated RhoA.
Constitutively Active RhoGTPases Induce EMT in HK2 Cells
We examined the effect of each mutant on cell morphology (Figure 4 ) and on the expression the EMT markers ( Figure 5 ). Noninfected cells and cells that were infected with a LacZ-expressing adenovirus had an epithelial morphology, whereas HK2 cells that were treated with aPBMC-CM for 48 h had a fibroblastic morphology. Expression of constitutively active RhoA, Rac1, and Cdc42 all promoted a fibroblastic morphology, especially at MOI of 50. Western blot analysis confirmed that the expression of constitutively active RhoA, Rac1, and Cdc42 in HK2 cells results in these cells undergoing EMT at higher MOI values ( Figure 5A ). With MOI of 20 and over, cellular expression of EDA was substantially elevated, whereas the level of E-cadherin and K19 was reduced at MOI of 40 and above. The shift of molecular markers from epithelial to myofibroblast, accompanied by the cells adopt- ing a characteristic fibroblast appearance, clearly indicates that the activation of RhoA, Rac1, and Cdc42 plays an important role in controlling EMT.
Dominant Negative RhoA Blocks aPBMC-CM-Mediated EMT
We also infected HK2 cells with adenovirus expressing dominant negative RhoA before aPBMC-CM stimulation. The activation of RhoA was significantly suppressed by expression of RhoAT19N (data not shown). Moreover, a MOI of 50 completely prevented the aPBMC-CM-induced morphologic changes (Figure 4) . However, whereas the addition of aPBMC-CM to HK2 cells resulted in the upregulation of EDA and the downregulation of E-cadherin and K19, as expected ( Figure 5A , second panel), infection with RhoAT19N blocked only the increases in EDA in a dose-dependent manner ( Figure  5D ) and had no effect on the suppression of either E-cadherin or K19 ( Figure 5 , B and C).
Downstream Effectors of RhoGTPases
HK2 cells that were stimulated with aPBMC-CM phosphorylated focal adhesion kinase (FAK) and myosin light chain (MLC) by 15 min, and phosphorylation was sustained for up to 16 h (Figure 6 ). Paxillin was phosphorylated after 5 min and remained phosphorylated up to 48 h ( Figure 6 ). HK2 cells that were infected with various doses of RhoAQ63L exhibited an increase in phosphorylation of MLC, FAK, and paxillin ( Figure  7A ). However, aPBMC-CM-induced phosphorylation of FAK, MLC, and paxillin was significantly reduced in a dose-dependent manner when cells were infected with various amounts of RhoAT19N construct ( Figure 7B ).
P21-activated protein kinase (PAK) is a downstream effector for Rac1 and Cdc42. aPBMC-CM induced PAK phosphorylation as early as 10 min, and PAK stayed phosphorylated up to 48 h ( Figure 6 ). HK2 cells that were infected with either Rac1Q61L or Cdc42Q61L upregulated PAK phosphorylation after 24 h of infection ( Figure 7C ).
HA1077 and Y-27632 completely abolished RhoAQ63L-induced changes in EDA expression, but neither inhibitor restored E-cadherin or K19 expression (Figure 8 ). Similar inhibitory profiles were observed when HK2 cells were stimulated with aPBMC-CM instead of RhoAQ63L. Collectively, these data suggest that the EMT that occurs in response to aPBMC-CM is dependent on signaling through the RhoA, Rac1, and Cdc42 pathways.
Discussion
Several in vitro studies have demonstrated that a single cytokine, such as TGF-␤, can induce cultured human epithelial cells to undergo EMT (8, 12, 16, 17) . However, in more physiologically relevant conditions in which aPBMC-CM was applied to epithelial cells, blockade of single cytokines by neutralizing antibodies showed little inhibition of EMT (8) . Thus, it seems likely that multiple cytokines may act synergistically to trigger EMT in vivo. The many cytokines present in aPBMC-CM are likely to activate various signaling pathways that then disturb the dynamic equilibrium state between a cell's transcription and transduction network and the local environment (2) . The global changes of gene expression determined by microarray provide valuable information of putative molecular mechanisms that drive EMT (8) . One set of factors that are involved with the EMT signaling network belong to the small RhoGTPases family. In this study, we found that RhoA, Rac1, and Cdc42 were activated in kidney epithelial cells shortly after the aPBMC-CM stimulation and directly contribute to the suppression of E-cadherin expression, as this could be reversed by toxin B, an inhibitor of small RhoGTPases. Our results are consistent with previous reports. For example, a RhoAdependent mechanism was implicated in TGF-␤-induced EMT (12), whereas activation of Cdc42 and Rac directly related to hepatocyte growth factor-induced cell scattering/spread by disrupting cell-cell junctions and rearrangement of the actin cytoskeleton (18, 19) . Using dominant negative forms of small RhoGTPases the formation of filopodia and lamellipodia and cell scattering were disrupted (18, 20) . Thus, our data, together with that of others, support the notion that small RhoGTPases play key RhoA promotes the formation of stress fibers and increased contractility, but a RhoA-induced increase in contractility is not sufficient to disrupt adherens junctions, because inhibition of RhoA only partially restores the epithelial phenotype of Ras transformed cells (21) (22) (23) (24) . However, Rac1 and Cdc42 are believed to be involved in the establishment and maintenance of epithelial intercellular adhesions (25) (26) (27) . In our experiment, even low levels of overexpression of constitutively active RhoA cause human epithelial cells to switch on the expression of the mesenchymal cell marker EDA, whereas higher levels of overexpression also decrease that of E-cadherin and K19. In contrast to the putative role of Rac1 and Cdc42 (25) (26) (27) , we found that overexpression of constitutively active Rac1 and Cdc42 in HK2 cells stimulated them to turn on the EMT program in a similar pattern to that observed in epithelial cells that were exposed to aPBMC-CM. Our data are more consistent with the observation that activated Rac promotes cell-cell adhesion breakdown in T47D mammary carcinoma cells (28) . One possibility is that these differences in response to Rac and Cdc42 are due to the differences in the cell types investigated. Another possibility is that when virally encoded constitutively active small RhoGTPases are expressed, their level of activity may be superphysiologic, inducing effects and cross-talk between signaling pathways that would not normally occur. However, in our experiments, we infected cells with a range of concentrations of adenoviruses to establish a dose-response effect and avoid this problem as far as possible. Finally, another factor that may relate to the paradoxic observations of Rac's involvement in transdifferentiation is that the nature of the extracellular matrix to which the cells adhere may account for different observations. For example, Tiam-expressing RasV12-transformed MDCK cells showed a fibroblast-like migratory phenotype when plated on collagen, but an epithelial phenotype when plated on laminin or fibronectin (29) .
The activation of small RhoGTPases is associated with that of specific downstream proteins. Thus, serine/threonine protein kinases of the ROCK family have been identified as downstream targets of RhoA, transducing Rho activation into stress fiber formation and focal adhesion assembly (30) . Understanding the molecular cascades of the small RhoGTPase pathways may help us to identify new therapeutic targets. For example, the ROCK inhibitor Y-27632 was shown to reverse tubulointerstitial fibrosis after unilateral ureteric obstruction (15) , a model that develops tubulointerstitial fibrosis via EMT (31) . Our data showed that aPBMC-CM induced phosphorylation of MLC, FAK, and paxillin and that this effect was inhibited by expression of dominant negative RhoA. Moreover, constitutively active RhoA stimulated phosphorylation of MLC, FAK, and paxillin in HK2 cells. Although our data suggest that RhoA initiates EMT via the ROCK/MLC/FAK/paxillin pathway, it leaves open the possible involvement of other members of the small RhoGTPases, such as RhoB and RhoC (32) . Because HK2 cells that were treated with aPBMC-CM leads to activation of RhoA pathways, as well as to activation of the Rac1/Cdc42 signaling pathway, and induces transdifferentiation events similar to those initiated by TGF-␤ (12), it is likely that small RhoGTPase pathways play key roles in the process of EMT. Clearly, further investigation of the role of RhoA, Rac1, and Cdc42 in transdifferentiation and in renal fibrosis is warranted.
Our results strongly suggested that small RhoGTPase signaling plays important roles in aPBMC-CM-mediated EMT. However, the contributions of some other pathways, such as the Smad pathway, should not be excluded (4, 33) . The latter's importance is illustrated in a mouse model of chronic renal injury, in which recombinant human BMP-7 showed therapeutic efficacy by inhibiting Smad-dependent TGF-␤1-induced EMT (34) . It is likely that parallel signaling pathways, such as Smad/ILK and RhoA/ROCK, work together in vivo (7) . 
